Company Profile • Life Sciences AI
Intelligencia AI
Teaching the pharmaceutical industry to price the risk of a drug before it bets the pipeline on it.
Teaching the pharmaceutical industry to price the risk of a drug before it bets the pipeline on it.
Drug development is a business built on informed bets, and most of them lose. By the industry's own accounting, only about 12% of new molecular entities that enter clinical trials ever reach patients. The other 88% consume years of work and billions of dollars before quietly disappearing. Intelligencia AI, a New York company founded in 2017, was built around a straightforward proposition: what if you could see the odds before you placed the bet?
The company's answer is a metric that pharma has long estimated by intuition and spreadsheet - PTRS, the probability of technical and regulatory success. It is the likelihood that a drug candidate will advance from one clinical phase to the next and, ultimately, win regulatory approval. Intelligencia AI turns that estimate into a data-backed score, and, notably, shows the work behind it.
To produce a number, the platform ingests and harmonizes more than 1.5 billion data points. These span the science - drug biology, indications, genes, proteins, targets, biological pathways - alongside regulatory designations, patents, funding, and the granular details of clinical trial design, setup, execution, and outcomes. Out of that thicket comes a single, defensible figure a portfolio committee can debate.
What separates the approach from the crowded field of "AI for pharma" is less the prediction than the transparency around it. The company reports greater than 80% prospective accuracy - predictions made before outcomes are known, rather than the flattering retrospective numbers that are easy to manufacture after the fact - and pairs each score with explainability, showing the relative contribution of every factor that shaped it.
The founders, Dimitrios Skaltsas and Vangelis Vergetis, did not arrive at the problem by accident. Skaltsas, the CEO, previously led McKinsey's New Ventures for big data and AI in pharmaceutical R&D, where he built machine-learning products for life sciences. He holds a law degree and an INSEAD MBA. The pair started Intelligencia AI to attack the what-ifs of human decision-making with software.
By 2021 the thesis had drawn capital and a marquee partner. The company closed a $12 million Series A led by MTIP, with Big Pi Ventures, Synetro Group, and ZS Associates participating, and announced an exclusive partnership with ZS to reduce risk in clinical development. That year it was also named to Forbes' list of AI companies to watch.
“Encoding a program's inherent risk into a single score helps a company decide whether to keep investing in a candidate - or to walk away.”
Intelligencia AI is an artificial-intelligence company for drug development. Its patented software scores how likely a drug is to clear each clinical phase and reach regulatory approval, then explains why - so R&D, business-development, and portfolio-strategy teams can make investment decisions on evidence rather than optimism.
Deciding which drug programs to fund, license, or kill has traditionally leaned on intuition. The most costly mistakes are the candidates a team should have discontinued earlier.
The platform assigns a probability of technical and regulatory success at every phase, with hundreds of dimensions of explainability behind each prediction.
Teams reallocate capital toward the assets most likely to reach patients - and away from the ones quietly draining the pipeline.
Every drug candidate runs a gauntlet. Intelligencia AI's platform is designed to attach a probability to each transition - not just the final approval - so teams see risk building phase by phase.
A patented, on-demand platform delivering AI-powered PTRS insights on individual assets, indications, and whole portfolios - built on proprietary harmonized data.
Analytics that assess and de-risk individual clinical programs across every phase, with explainability into the drivers behind each prediction.
Direct access to the harmonized, curated dataset of 1.5 billion+ clinical and biological data points as a recurring subscription.
Tailored analytical engagements that apply the platform and data to a client's specific therapeutic areas and strategic questions.
Most AI in drug development behaves like a black box. Intelligencia AI made the opposite bet: in a regulated industry, a number no one can explain to a review committee - or to the FDA - is a number no one will act on. The platform surfaces the relative weight of each factor driving a score, from trial design to regulatory history.
It sits alongside pipeline-intelligence and analytics providers such as Citeline, GlobalData, and IQVIA, and competes with the internal data-science teams that large pharmas build in-house. Its customers are broad: mid-to-large pharmaceutical and biotech companies, contract research organizations, consultancies, and financial-market players - banks and hedge funds - that need to price the risk of a drug asset.
“When ZS needed to narrow a client from 60 tumor segments to 10, it used Intelligencia AI's data and Portfolio Optimizer.”
Recurring software and data subscriptions to the Portfolio Optimizer platform, plus bespoke custom-insight engagements. Estimated annual revenue around $23M.
A ~110-person team blending pharmaceutical R&D domain knowledge with machine learning, biomedical data curation, and quality control.
R&D, business development, licensing, and portfolio strategy teams across pharma, biotech, CROs, consultancies, and financial markets.
Dimitrios Skaltsas and Vangelis Vergetis start Intelligencia AI to apply artificial intelligence to the risk of drug development.
A Series A led by MTIP closes; an exclusive partnership with global services firm ZS is announced. The company is named to Forbes' AI companies to watch.
The company brings its patented SaaS PTRS platform to pharma, CRO, and financial-market clients.
Nature Biotechnology and trade press spotlight AI probability-of-success methods, with Intelligencia AI among the named players.
It provides an AI platform that predicts a drug candidate's probability of technical and regulatory success (PTRS) - how likely it is to advance through clinical phases and win approval - so pharma and biotech teams make better R&D and investment decisions.
It was founded in New York in 2017 by Dimitrios Skaltsas (Co-Founder & CEO) and Vangelis Vergetis (Co-Founder).
The company reports greater than 80% prospective accuracy and around 91% retrospective accuracy in forecasting asset success, validated across clinical development stages.
Mid-sized to large pharmaceutical and biotech companies, contract research organizations, consultancies, and financial-market participants such as banks and hedge funds.
A $12M Series A in 2021 led by MTIP, with total reported funding of roughly $15.5M. Investors include Big Pi Ventures, Synetro Group, and ZS Associates.